Determining the best course of treatment for younger patients with relapsed/refractory CLL
The evolving treatment landscape in multiple myeloma and its implications for clinical practice
Comparing ibrutinib efficacy and toxicity levels by age for patients with CLL/SLL
Frontline treatment of elderly multiple myeloma patients and management of relapse/refractory
Enrique Ocio et al.
What is the role of allogeneic stem cell transplantation in CLL in the light of novel drugs?
What does a physician need to consider when treating relapsed or refractory myeloma?